216 related articles for article (PubMed ID: 32961077)
1. Contemplating HPV vaccination in Japan during the time of COVID-19.
Miyoshi A; Ueda Y; Kimura T
Hum Vaccin Immunother; 2021 Mar; 17(3):836-837. PubMed ID: 32961077
[TBL] [Abstract][Full Text] [Related]
2. Human Papillomavirus Vaccination After COVID-19.
Toh ZQ; Russell FM; Garland SM; Mulholland EK; Patton G; Licciardi PV
JNCI Cancer Spectr; 2021 Apr; 5(2):pkab011. PubMed ID: 33748668
[TBL] [Abstract][Full Text] [Related]
3. The European response to the WHO call to eliminate cervical cancer as a public health problem.
Arbyn M; Gultekin M; Morice P; Nieminen P; Cruickshank M; Poortmans P; Kelly D; Poljak M; Bergeron C; Ritchie D; Schmidt D; Kyrgiou M; Van den Bruel A; Bruni L; Basu P; Bray F; Weiderpass E
Int J Cancer; 2021 Jan; 148(2):277-284. PubMed ID: 32638362
[TBL] [Abstract][Full Text] [Related]
4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
5. No Vacillation on HPV Vaccination.
Sipp D; Frazer IH; Rasko JEJ
Cell; 2018 Mar; 172(6):1163-1167. PubMed ID: 29522737
[TBL] [Abstract][Full Text] [Related]
6. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of human papillomavirus vaccination in young Japanese women: a retrospective multi-municipality study.
Tozawa-Ono A; Kamada M; Teramoto K; Hareyama H; Kodama S; Kasai T; Iwanari O; Koizumi T; Ozawa N; Suzuki M; Kinoshita K
Hum Vaccin Immunother; 2021 Apr; 17(4):950-954. PubMed ID: 33121340
[TBL] [Abstract][Full Text] [Related]
8. The last strategy for re-dissemination of HPV vaccination in Japan while still under the suspension of the governmental recommendation.
Ueda Y; Yagi A; Abe H; Nakagawa S; Minekawa R; Kuroki H; Miwa A; Kimura T
Sci Rep; 2020 Sep; 10(1):16091. PubMed ID: 32999408
[TBL] [Abstract][Full Text] [Related]
9. Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation.
Larson HJ; Wilson R; Hanley S; Parys A; Paterson P
Hum Vaccin Immunother; 2014; 10(9):2543-50. PubMed ID: 25483472
[TBL] [Abstract][Full Text] [Related]
10. Corrected human papillomavirus vaccination rates for each birth fiscal year in Japan.
Nakagawa S; Ueda Y; Yagi A; Ikeda S; Hiramatsu K; Kimura T
Cancer Sci; 2020 Jun; 111(6):2156-2162. PubMed ID: 32248632
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
12. Asking about human papillomavirus vaccination and the usefulness of registry validation: a study of young women recruited using Facebook.
Gunasekaran B; Jayasinghe Y; Brotherton JM; Fenner Y; Moore EE; Wark JD; Fletcher A; Tabrizi SN; Garland SM
Vaccine; 2015 Feb; 33(6):826-31. PubMed ID: 25444782
[TBL] [Abstract][Full Text] [Related]
13. A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation.
Ishimoto T; Yagi A; Nakajima K; Okamoto N; Yukimitsu E; Kawasaki M; Kawae Y; Hayasaka S; Ueda Y; Kimura T
Hum Vaccin Immunother; 2023 Aug; 19(2):2229222. PubMed ID: 37462048
[TBL] [Abstract][Full Text] [Related]
14. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of Human Papillomavirus Vaccine for Prevention of Cervical Abnormalities in Miyagi, Japan.
Ozawa N; Ito K; Tase T; Metoki H; Yaegashi N
Tohoku J Exp Med; 2016 Oct; 240(2):147-151. PubMed ID: 27746423
[TBL] [Abstract][Full Text] [Related]
16. Educational intervention for women in Japan coming of age for cervical cancer screening who grew up during the suspended HPV-vaccination-program.
Miyoshi A; Ueda Y; Yagi A; Kimura T; Kobayashi E; Hiramatsu K; Nakagawa S; Kimura T
Hum Vaccin Immunother; 2021 Nov; 17(11):4418-4422. PubMed ID: 35016492
[TBL] [Abstract][Full Text] [Related]
17. The estimated impact of natural immunity on the effectiveness of human papillomavirus vaccination.
Matthijsse SM; Hontelez JAC; Naber SK; van Rosmalen J; Rozemeijer K; Penning C; Bakker R; van Ballegooijen M; de Kok IMCM; de Vlas SJ
Vaccine; 2015 Oct; 33(41):5357-5364. PubMed ID: 26348405
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.
Yagi A; Nakagawa S; Ueda Y; Oka E; Ikeda S; Kakuda M; Kobayashi E; Ito Y; Katayama K; Hirai K; Nakayama T; Kimura T
Cancer Sci; 2024 Mar; 115(3):916-925. PubMed ID: 38158850
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of vaccination against HPV in Israel.
Ginsberg GM; Fisher M; Ben-Shahar I; Bornstein J
Vaccine; 2007 Sep; 25(37-38):6677-91. PubMed ID: 17706844
[TBL] [Abstract][Full Text] [Related]
20. A survey of Japanese mothers on the effectiveness of the Ministry of Health, Labor and Welfare's revised HPV vaccine leaflet.
Shiomi M; Ueda Y; Abe H; Yagi A; Sakiyama K; Kimura T; Tanaka Y; Ohmichi M; Ichimura T; Sumi T; Murata H; Okada H; Nakai H; Matsumura N; Saito J; Takagi T; Horikoshi Y; Shimura K
Hum Vaccin Immunother; 2020 Oct; 16(10):2555-2558. PubMed ID: 32243236
[No Abstract] [Full Text] [Related]
[Next] [New Search]
